Editorial
Testosterone Deficiency at the Crossroads of Cardiometabolic Complications in CKD

https://doi.org/10.1053/j.ajkd.2014.06.002Get rights and content

Section snippets

Acknowledgements

I thank my colleagues for never ending support and enthusiasm toward research curiosity.

Support: This editorial was produced without direct funding. Dr Carrero acknowledges grant support from the Swedish Research Council.

Financial Disclosure: Dr Carrero reports having received speaking fees from Bayer Pharmaceuticals (the manufacturer of Nebido) in 2013 and participates in an investigator-driven randomized controlled trial on testosterone replacement therapy in hypogonadal men undergoing

References (36)

  • Dousdampanis P, Trigka K, Fourtounas C, Bargman JM. Role of testosterone in the pathogenesis, progression, prognosis...
  • P. Iglesias et al.

    Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options

    J Nephrol

    (2012)
  • J.J. Carrero et al.

    Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD

    Clin J Am Soc Nephrol

    (2012)
  • M.I. Yilmaz et al.

    Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease

    Clin J Am Soc Nephrol

    (2011)
  • J.J. Carrero et al.

    Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease

    Nephrol Dial Transplant

    (2011)
  • O. Gungor et al.

    Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging?

    Clin J Am Soc Nephrol

    (2010)
  • J.J. Carrero et al.

    Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease

    Nephrol Dial Transplant

    (2012)
  • Ekart R, Taskovska M, Hojs N, Bevc S, Hojs R. Testosterone and hemoglobin in hemodialysis male and female patients...
  • Cited by (10)

    • The Other Way Around: Living With Chronic Kidney Disease From the Perspective of Men

      2022, Seminars in Nephrology
      Citation Excerpt :

      On the one hand, animal studies attribute these differences to deleterious effects of testosterone.21-23 However, this causality is difficult to reconcile with literature regarding the association between testosterone deficiency and adverse clinical outcomes in men with CKD, and the role of testosterone replacement therapy on managing complications of CKD such as anemia or muscle wasting.24,25 Other animal studies have reported that although nitric oxide production is lower in male compared with female animals,26 proinflammatory mediators of kidney injury27,28 and oxidative stress in the kidney are higher.29

    • Hypogonadism associated with muscle atrophy, physical inactivity and ESA hyporesponsiveness in men undergoing haemodialysis

      2017, Nefrologia
      Citation Excerpt :

      Chronic kidney disease (CKD) involves alterations in body homeostasis and metabolic disturbances (including hormone secretion disorders and altered response to hormones in target tissues), resulting in endocrine dysfunctions that may contribute to the increased mortality in CKD patients.1 Hypogonadism, hallmarked by testosterone deficiency is a common endocrine disorder among men undergoing dialysis, with a prevalence ranging from 35 to 50% in recent studies.2–4 Various studies link hypogonadism with mortality risk among hemodialysis patients,5,6 but the pathways by which this risk may be mediated are not well known.

    • Hypogonadism associated with muscle atrophy, physical inactivity and ESA hyporesponsiveness in men undergoing haemodialysis

      2017, Nefrologia
      Citation Excerpt :

      Chronic kidney disease (CKD) involves alterations in body homeostasis and metabolic disturbances (including hormone secretion disorders and altered response to hormones in target tissues), resulting in endocrine dysfunctions that may contribute to the increased mortality in CKD patients.1 Hypogonadism, hallmarked by testosterone deficiency is a common endocrine disorder among men undergoing dialysis, with a prevalence ranging from 35 to 50% in recent studies.2–4 Various studies link hypogonadism with mortality risk among hemodialysis patients,5,6 but the pathways by which this risk may be mediated are not well known.

    • Testosterone deficiency in male organ transplant recipients

      2022, International Journal of Impotence Research
    View all citing articles on Scopus
    View full text